Relationship between drug-induced interstitial lung diseases and cytochrome P450 polymorphisms

Current Opinion in Pulmonary Medicine

Volumn 16, Issue 5, 2010, Pages 496-502

  Wijnen, Petal A H M ^a   Bekers, Otto ^a   Drent, Marjolein ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

adverse drug reactions; cytochrome P450 polymorphisms; drug induced pneumonitis; fenfluramine; lung; xenobiotics

Indexed keywords

AMIODARONE; ANTICONVULSIVE AGENT; BENZO[A]PYRENE; CAFFEINE; CARBAMAZEPINE; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2A6; CYTOCHROME P450 2C; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A; DEXFENFLURAMINE; FENFLURAMINE; HYPERICUM PERFORATUM EXTRACT; ISOENZYME; NAPROXEN; PARACETAMOL; PHENOBARBITAL; PSYCHOTROPIC AGENT; RIFAMPICIN; STEROID; TACROLIMUS; THEOPHYLLINE; VERAPAMIL; XENOBIOTIC AGENT;

CYP GENE; ENZYME ACTIVITY; ENZYME METABOLISM; GENE; GENETIC POLYMORPHISM; GRAPEFRUIT JUICE; HUMAN; INTERSTITIAL LUNG DISEASE; LUNG PARENCHYMA; PNEUMONIA; PRESCRIPTION; PROTEIN FAMILY; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TISSUE INJURY;

CYTOCHROME P-450 ENZYME SYSTEM; DRUG THERAPY; HUMANS; LUNG DISEASES, INTERSTITIAL; PHARMACOGENETICS; POLYMORPHISM, GENETIC; RISK FACTORS; XENOBIOTICS;

EID: 77955272130     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/MCP.0b013e32833c06f1     Document Type: Review

References (64)

1. Camus P, Fanton A, Bonniaud P, et al. Interstitial lung disease induced by drugs and radiation. Respiration 2004; 71:301-326. (Pubitemid 39179164)
2. Wijnen PA, Drent M, Nelemans PJ, et al. Role of cytochrome P450 polymorphisms in the development of pulmonary drug toxicity: a case-control study in the Netherlands. Drug Saf 2008; 31:1125-1134.
3. Foucher P, Biour M, Blayac JP, et al. Drugs that may injure the respiratory system. Eur Respir J 1997; 10:265-279.
4. Bressler R. Grapefruit juice and drug interactions: exploring mechanisms of this interaction and potential toxicity for certain drugs. Geriatrics 2006; 61:12-18.
5. Camus P, Kudoh S, Ebina M. Interstitial lung disease associated with drug therapy. Br J Cancer 2004; 91 (Suppl 2):S18-S23. (Pubitemid 39331428)
6. Drent M, Singh S, Gorgels AP, et al. Drug-induced pneumonitis and heart failure simultaneously associated with venlafaxine. Am J Respir Crit Care Med 2003; 167:958-961.
7. Nemery B, Bast A, Behr J, et al. Interstitial lung disease induced by exogenous agents: factors governing susceptibility. Eur Respir J Suppl 2001; 32:30s-42s.
8. Kalow W, Tang BK, Endrenyi L. Hypothesis: comparisons of inter-and intraindividual variations can substitute for twin studies in drug research. Pharmacogenetics 1998; 8:283-289.
9. Castell JV, Donato MT, Gomez-Lechon MJ. Metabolism and bioactivation of toxicants in the lung: the in vitro cellular approach. Exp Toxicol Pathol 2005; 57 (Suppl 1):189-204.
10. Ding X, Kaminsky LS. Human extrahepatic cytochromes P450: function in xenobiotic metabolism and tissue-selective chemical toxicity in the respiratory and gastrointestinal tracts. Annu Rev Pharmacol Toxicol 2003; 43:149-173.
11. Kirchheiner J, Seeringer A. Clinical implications of pharmacogenetics of cytochrome P450 drug metabolizing enzymes. Biochim Biophys Acta 2007; 1770:489-494.
12. Nishimura M, Yaguti H, Yoshitsugu H, et al. Tissue distribution of mRNA expression of human cytochrome P450 isoforms assessed by high-sensitivity real-time reverse transcription PCR. Yakugaku Zasshi 2003; 123:369-375.
13. Sarikaya D, Bilgen C, Kamataki T, et al. Comparative cytochrome P450-1A1,-2A6,-2B6,-2C,-2D6,-2E1,-3A5 and-4B1 expressions in human larynx tissue analysed at mRNA level. Biopharm Drug Dispos 2006; 27:353-359.
14. Carlson GP. Critical appraisal of the expression of cytochrome P450 enzymes in human lung and evaluation of the possibility that such expression provides evidence of potential styrene tumorigenicity in humans. Toxicology 2008; 254:1-10.
15. Ereshefsky L, Dugan D. Review of the pharmacokinetics, pharmacogenetics, and drug interaction potential of antidepressants: focus on venlafaxine. Depress Anxiety 2000; 12 (Suppl 1):30-44.
16. Nelson DR. Introductory remarks on human CYPs. Drug Metab Rev 2002; 34:1-5.
17. Oinonen T, Lindros KO. Zonation of hepatic cytochrome P-450 expression and regulation. Biochem J 1998; 329 (Pt 1):17-35.
18. Krishna DR, Klotz U. Extrahepatic metabolism of drugs in humans. Clin Pharmacokinet 1994; 26:144-160.
19. Hukkanen J, Pelkonen O, Raunio H. Expression of xenobiotic-metabolizing enzymes in human pulmonary tissue: possible role in susceptibility for ILD. Eur Respir J Suppl 2001; 32:122s-126s.
20. Hukkanen J, Pelkonen O, Hakkola J, et al. Expression and regulation of xenobiotic-metabolizing cytochrome P450 (CYP) enzymes in human lung. Crit Rev Toxicol 2002; 32:391-411.
21. Zhang JY, Wang Y, Prakash C. Xenobiotic-metabolizing enzymes in human lung. Curr Drug Metab 2006; 7:939-948.
22. Nelson DR. Cytochrome P450 nomenclature, 2004. Methods Mol Biol 2006; 320:1-10.
23. Evans WE, Relling MV. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 1999; 286:487-491.
24. Rendic S, Di Carlo FJ. Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metab Rev 1997; 29:413-580.
25. Jaquenoud Sirot E, van der Velden JW, Rentsch K, et al. Therapeutic drug monitoring and pharmacogenetic tests as tools in pharmacovigilance. Drug Saf 2006; 29:735-768.
26. Miners JO, Birkett DJ. The use of caffeine as a metabolic probe for human drug metabolizing enzymes. Gen Pharmacol 1996; 27:245-249.
27. Miners JO, Coulter S, Tukey RH, et al. Cytochromes P450, 1A2, and 2C9 are responsible for the human hepatic O-demethylation of R-and S-naproxen. Biochem Pharmacol 1996; 51:1003-1008.
28. Fuhr U. Drug interactions with grapefruit juice: extent, probable mechanism and clinical relevance. Drug Saf 1998; 18:251-272.
29. Zevin S, Benowitz NL. Drug interactions with tobacco smoking: an update. Clin Pharmacokinet 1999; 36:425-438.
30. Zhang ZY, Kaminsky LS. Characterization of human cytochromes P450 involved in theophylline 8-hydroxylation. Biochem Pharmacol 1995; 50:205-211.
31. Ou-Yang DS, Huang SL, Wang W, et al. Phenotypic polymorphism and gender-related differences of CYP1A2 activity in a Chinese population. Br J Clin Pharmacol 2000; 49:145-151.
32. Rettie AE, Jones JP. Clinical and toxicological relevance of CYP2C9: drugdrug interactions and pharmacogenetics. Annu Rev Pharmacol Toxicol 2005; 45:477-494.
33. Pavek P, Dvorak Z. Xenobiotic-induced transcriptional regulation of xenobiotic metabolizing enzymes of the cytochrome P450 superfamily in human extrahepatic tissues. Curr Drug Metab 2008; 9:129-143.
34. Lee CR, Goldstein JA, Pieper JA. Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data. Pharmacogenetics 2002; 12:251-263.
35. Bravo-Villalta HV, Yamamoto K, Nakamura K, et al. Genetic polymorphism of CYP2C9 and CYP2C19 in a Bolivian population: an investigative and comparative study. Eur J Clin Pharmacol 2005; 61:179-184.
36. Higashi MK, Veenstra DL, Kondo LM, et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 2002; 287:1690-1698.
37. Heimark LD, Gibaldi M, Trager WF, et al. The mechanism of the warfarinrifampin drug interaction in humans. Clin Pharmacol Ther 1987; 42:388-394.
38. Lee SJ, Kim WY, Kim H, et al. Identification of new CYP2C19 variants exhibiting decreased enzyme activity in the metabolism of S-mephenytoin and omeprazole. Drug Metab Dispos 2009; 37:2262-2269.
39. Poolsup N, Li Wan Po A, Knight TL. Pharmacogenetics and psychopharmacotherapy. J Clin Pharm Ther 2000; 25:197-220.
40. Flockhart DA. Drug interactions and the cytochrome P450 system: the role of cytochrome P450 2C19. Clin Pharmacokinet 1995; 29 (Suppl 1):45-52.
41. Zhou HH, Anthony LB, Wood AJ, et al. Induction of polymorphic 40-hydroxylation of S-mephenytoin by rifampicin. Br J Clin Pharmacol 1990; 30:471-475.
42. Gerbal-Chaloin S, Pascussi JM, Pichard-Garcia L, et al. Induction of CYP2C genes in human hepatocytes in primary culture. Drug Metab Dispos 2001; 29:242-251.
43. Gough AC, Smith CA, Howell SM, et al. Localization of the CYP2D gene locus to human chromosome 22q13.1 by polymerase chain reaction, in situ hybridization, and linkage analysis. Genomics 1993; 15:430-432.
44. Alam DA, Sharma RP. Cytochrome enzyme genotype and the prediction of therapeutic response to psychotropics. Psychiatric Annals 2001; 31:715-722.
45. Guidice JM, Marez D, Sabbagh N, et al. Evidence for CYP2D6 expression in human lung. Biochem Biophys Res Commun 1997; 241:79-85.
46. Huang Z, Fasco MJ, Spivack S, et al. Comparisons of CYP2D messenger RNA splice variant profiles in human lung tumors and normal tissues. Cancer Res 1997; 57:2589-2592.
47. DeVane CL, Nemeroff CB. 2002 guide to psychtropic drug interactions. Primary Psychiatry 2002; 9:28-57.
48. de Leon J, Barnhill J, Rogers T, et al. Pilot study of the cytochrome P450-2D6 genotype in a psychiatric state hospital. Am J Psychiatry 1998; 155:1278-1280.
49. Daly AK, Brockmoller J, Broly F, et al. Nomenclature for human CYP2D6 alleles. Pharmacogenetics 1996; 6:193-201.
50. Bradford LD. CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics 2002; 3:229-243.
51. Eichelbaum M, Evert B. Influence of pharmacogenetics on drug disposition and response. Clin Exp Pharmacol Physiol 1996; 23:983-985.
52. Schroth W, Goetz MP, Hamann U, et al. Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA 2009; 302:1429-1436.
53. Wijnen PA, Limantoro I, Drent M, et al. Depressive effect of an antidepressant: therapeutic failure of venlafaxine in a case lacking CYP2D6 activity. Ann Clin Biochem 2009; 46:527-530.
54. Wojnowski L, Hustert E, Klein K, et al. Re: modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J Natl Cancer Inst 2002; 94:630-631; author reply 631-632.
55. Amirimani B, Ning B, Deitz AC, et al. Increased transcriptional activity of the CYP3A4-1B promoter variant. Environ Mol Mutagen 2003; 42:299-305.
56. Ball SE, Scatina J, Kao J, et al. Population distribution and effects on drug metabolism of a genetic variant in the 50 promoter region of CYP3A4. Clin Pharmacol Ther 1999; 66:288-294.
57. Roy JN, Lajoie J, Zijenah LS, et al. CYP3A5 genetic polymorphisms in different ethnic populations. Drug Metab Dispos 2005; 33:884-887.
58. Lee SJ, Usmani KA, Chanas B, et al. Genetic findings and functional studies of human CYP3A5 single nucleotide polymorphisms in different ethnic groups. Pharmacogenetics 2003; 13:461-472.
59. Op den Buijsch RA, Christiaans MH, Stolk LM, et al. Tacrolimus pharmacokinetics and pharmacogenetics: influence of adenosine triphosphate-binding cassette B1 (ABCB1) and cytochrome (CYP) 3A polymorphisms. Fundam Clin Pharmacol 2007; 21:427-435.
60. Spear BB, Heath-Chiozzi M, Huff J. Clinical application of pharmacogenetics. Trends Mol Med 2001; 7:201-204.
61. Wijnen PA, Linssen CF, Haenen GR, et al. Variant VKORC1 and CYP2C9 alleles in patients with diffuse alveolar hemorrhage caused by oral anticoagulants. Mol Diagn Ther 2010; 14:23-30.
62. Daly AK. Individualized drug therapy. Curr Opin Drug Discov Devel 2007; 10:29-36.
63. Ekbal NJ, Holt DW, Macphee IA. Pharmacogenetics of immunosuppressive drugs: prospect of individual therapy for transplant patients. Pharmacogenomics 2008; 9:585-596.
64. Wijnen PA, Drent M, van Dieijen-Visser MP, et al. Pharmacogenetic testing after a simple DNA isolation method on buccal swab samples. Pharmacogenomics 2009; 10:983-987.